Skip to Main content Skip to Navigation
Journal articles

Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening

Abstract : trans-Sialidase from Trypanosoma cruzi (TcTS) has emerged as a potential drug target for treatment of Chagas disease. Here, we report the results of virtual screening for the discovery of novel TcTS inhibitors, which targeted both the sialic acid and sialic acid acceptor sites of this enzyme. A library prepared from the Evotec database of commercially available compounds was screened using the molecular docking program GOLD, following the application of drug-likeness filters. Twenty-three compounds selected from the top-scoring ligands were purchased and assayed using a fluorimetric assay. Novel inhibitor scaffolds, with IC 50 values in the submillimolar range were discovered. The 3-benzothiazol-2-yl-4-phenyl-but-3-enoic acid scaffold was studied in more detail, and TcTS inhibition was confirmed by an alternative sialic acid transfer assay. Attempts to obtain crystal structures of these compounds with TcTS proved unsuccessful but provided evidence of ligand binding at the active site.
Complete list of metadatas

Cited literature [33 references]  Display  Hide  Download

https://hal-pasteur.archives-ouvertes.fr/pasteur-02554114
Contributor : Alejandro Buschiazzo <>
Submitted on : Saturday, April 25, 2020 - 12:35:01 AM
Last modification on : Friday, October 16, 2020 - 11:58:02 AM

Identifiers

Collections

Citation

João Neres, Mark Brewer, Laura Ratier, Horacio Botti, Alejandro Buschiazzo, et al.. Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening. Bioorganic and Medicinal Chemistry Letters, Elsevier, 2009, 19 (3), pp.589-596. ⟨10.1016/j.bmcl.2008.12.065⟩. ⟨pasteur-02554114⟩

Share

Metrics

Record views

42